Literature DB >> 20596843

Her-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not Her-2 amplification.

Dimitrios Papavasileiou1, Konstantinos Tosios, Panos Christopoulos, Nikolaos Goutas, Dimitrios Vlachodimitropoulos.   

Abstract

Based on the prognostic role of Her-2 amplification and protein overexpression in breast cancer, various studies have been performed in oral squamous cell carcinomas (OSCC) with inconsistent results. As in invasive breast carcinomas Her-2 overexpression has been related to an increased number of chromosome 17 copies, a common chromosomal alteration in OSCC, we evaluated the association between polysomy 17 and Her-2 protein expression in a series of primary OSCC. Forty-one incisional biopsies of primary OSCC were included in the study. Protein expression was evaluated immunochistochemically with CB11 mouse monoclonal anti-human antibody. The reaction was arbitrarily characterized as absent, faint, moderate, and strong, and staining pattern as cytoplasmic and membranous. Positive cases were analyzed by chromogenic in situ hybridisation (CISH) to access Her-2 status. The association between polysomy 17 and Her-2 expression was checked by Fisher's exact test. Four cases were negative and 37 cases were positive for Her-2. Staining was faint in 15 cases and moderate in 22 cases. CISH showed that all cases with faint staining were diploid, while from the cases with moderate staining 10 were diploid and 12 polysomic for chromosome 17. Thirteen cases showed purely cytoplasmic staining, while in 24 there were areas of both cytoplasmic and membranous staining. There was a statistically significant correlation between intensity of the reaction and polysomy 17 (P = 0.0036), in particular for cases with both cytoplasmic and membranous staining (P = 0.0128). In some OSCC Her-2 immunohistochemical expression may be associated with chromosome 17 polysomy and not Her-2 amplification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20596843      PMCID: PMC2811573          DOI: 10.1007/s12105-009-0134-1

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  57 in total

1.  Chromosome 17 abnormalities in squamous cell carcinoma of the oral cavity, and its relationship with p53 and Bcl-2 expression.

Authors:  A Kanekawa; T Tsuji; A Oga; K Sasaki; F Shinozaki
Journal:  Anticancer Res       Date:  1999 Jan-Feb       Impact factor: 2.480

2.  HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.

Authors:  A Sáez; F J Andreu; M A Seguí; M L Baré; S Fernández; C Dinarés; M Rey
Journal:  Breast       Date:  2005-11-14       Impact factor: 4.380

3.  Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.

Authors:  T Ekberg; M Nestor; M Engström; H Nordgren; K Wester; J Carlsson; M Anniko
Journal:  Int J Oncol       Date:  2005-05       Impact factor: 5.650

4.  Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.

Authors:  Wedad M Hanna; Kevin Kwok
Journal:  Mod Pathol       Date:  2006-04       Impact factor: 7.842

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

6.  Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.

Authors:  Michael Bilous; Adrienne Morey; Jane Armes; Margaret Cummings; Glenn Francis
Journal:  Pathology       Date:  2006-04       Impact factor: 5.306

7.  Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck.

Authors:  Carlynn Willmore-Payne; Joseph A Holden; Lester J Layfield
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

8.  Telomere length on chromosome 17q shortens more than global telomere length in the development of breast cancer.

Authors:  Fariborz Rashid-Kolvear; Melania Pintilie; Susan J Done
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

9.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2007       Impact factor: 5.534

10.  Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.

Authors:  Marta Salido; Ignasi Tusquets; Josep M Corominas; Marta Suarez; Blanca Espinet; Cristina Corzo; Meritxell Bellet; Xavier Fabregat; Sergi Serrano; Francesc Solé
Journal:  Breast Cancer Res       Date:  2005-01-26       Impact factor: 6.466

View more
  4 in total

1.  Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population.

Authors:  Yumna Adnan; Syed Muhammad Adnan Ali; Muhammad Sohail Awan; Romana Idress; Muhammad Ozair Awan; Hasnain Ahmed Farooqui; Hammad Afzal Kayani
Journal:  PLoS One       Date:  2022-05-11       Impact factor: 3.752

2.  Cytogenetic significance of chromosome 17 aberrations and P53 gene mutations as prognostic markers in oral squamous cell carcinoma.

Authors:  Walid Zedan; Mohamed I Mourad; Sherin M Abd El-Aziz; Nagla M Salamaa; Asem A Shalaby
Journal:  Diagn Pathol       Date:  2015-02-22       Impact factor: 2.644

3.  Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.

Authors:  Xiangdong Liu; Yan Zheng; Chuanwu Qiao; Fei Qv; Jingnan Wang; Butong Ding; Yuping Sun; Yunshan Wang
Journal:  Diagn Pathol       Date:  2015-05-09       Impact factor: 2.644

4.  Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases.

Authors:  Marinela Bostan; Georgiana Gabriela Petrică-Matei; Gabriela Ion; Nicoleta Radu; Mirela Mihăilă; Răzvan Hainăroşie; Lorelei Irina Braşoveanu; Viviana Roman; Carolina Constantin; Monica Teodora Neagu
Journal:  Exp Ther Med       Date:  2019-10-25       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.